ArticleCell2016
Crystal Structure of the Human Cannabinoid Receptor CB
Open access · greenAbstract read
In one paragraph
Article in Cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 280 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
280citing papers in PubMed, 1 pooled it
70.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
280 citing papers in PubMed, 1 synthesis or guideline pooled it, 666 citations in OpenAlex.
- Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.International journal of molecular sciences · 2020Pooled it
- Universal pipeline for high-resolution GPCR structure determination.Nature structural & molecular biology · 2026Article
- Mechanisms of Different Brainstem Nuclei Involved in Electroacupuncture-Induced Analgesia.Chinese journal of integrative medicine · 2026Review
- Dimethylindanoylindole Isomers Revealed Different Pharmacological Profiles at CB1 and CB2 Cannabinoid Receptors.ACS bio & med chem Au · 2026Article
- Article
- Cyclic Monoterpene-Aromatic Hybrids from Chiral Pool Terpenoid Ketones: Practical Synthetic Methodology for Accessing Them and In Silico Assessment as Cannabinoid Receptor CB1/CB2 Ligands.Molecules (Basel, Switzerland) · 2026Article
- Library Docking for Cannabinoid-2 Receptor Ligands.Journal of medicinal chemistry · 2026Article
- Dynamic mechanism for subtype selectivity of endocannabinoids.The Journal of biological chemistry · 2026Article
- Leveraging machine learning for selective cannabinoid ligand discovery: methods, challenges, and opportunities.Expert opinion on drug discovery · 2026Review
- Article
- Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Library docking for Cannabinoid-2 Receptor ligands.bioRxiv : the preprint server for biology · 2026Article
- A Novel Approach for the Synthesis of Peripherally Acting Dual Target Inhibitor of Cannabinoid-1 (CB1 Receptor) and Inducible Nitric Oxide Synthase (iNOS) (Molecules (Basel, Switzerland) · 2026Article
- Sequence constraints predispose Class D GPCRs to follow an atypical activation mechanism.bioRxiv : the preprint server for biology · 2026Article
- Chemical Probes for Investigating the Endocannabinoid System.Current topics in behavioral neurosciences · 2026Review
- Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- Differential Evolution for Docking Simulations.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Structural Basis of GPCR-Biased Modulation.Handbook of experimental pharmacology · 2026Review
- Biosynthesis, Chemical Synthesis, and Pharmacological Evaluation of Lyngbyapeptin A as a GPCR Antagonist of Motilin, Cannabinoid, and Amylin Receptors.Journal of natural products · 2025Article
- Article
220 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors at 8 institutions in 2 countries.
Tian HuaiHuman Institute, ShanghaiTech University, Shanghai 201210, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Kiran VemuriCenter for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
Mengchen PuNational Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Lu QuiHuman Institute, ShanghaiTech University, Shanghai 201210, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Gye Won HanDepartments of Biological Sciences and Chemistry, Bridge Institute, University of Southern California, Los Angeles, CA 90089, USA.
Yiran WuiHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Suwen ZhaoiHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Wenqing ShuiiHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Shanshan LiiHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Anisha KordeCenter for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
Robert B LaprairieDepartments of Molecular Therapeutics and Neuroscience, The Scripps Research Institute, Jupiter, FL 33458, USA.
Edward L StahlDepartments of Molecular Therapeutics and Neuroscience, The Scripps Research Institute, Jupiter, FL 33458, USA.
Jo-Hao HoDepartments of Molecular Therapeutics and Neuroscience, The Scripps Research Institute, Jupiter, FL 33458, USA.
Nikolai ZvonokCenter for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
Han ZhouCenter for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
Irina KufarevaUniversity of California, San Diego, La Jolla, CA 92093, USA.
Beili WuCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Qiang ZhaoCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Michael A HansonGPCR Consortium, San Marcos, CA 92078, USA.
Laura M BohnDepartments of Molecular Therapeutics and Neuroscience, The Scripps Research Institute, Jupiter, FL 33458, USA. Electronic address: lbohn@scripps.edu.
Alexandros MakriyannisCenter for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA. Electronic address: a.makriyannis@northeastern.edu.
Raymond C StevensiHuman Institute, ShanghaiTech University, Shanghai 201210, China; Departments of Biological Sciences and Chemistry, Bridge Institute, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: stevens@shanghaitech.edu.cn.
Zhi-Jie LiuiHuman Institute, ShanghaiTech University, Shanghai 201210, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: liuzhj@shanghaitech.edu.cn.
Northeastern University · USShanghaiTech University · CNChinese Academy of Sciences · CNScripps Research Institute · USInstitute of Biophysics · CNClinical Research Consortium · USUniversity of California, San Diego · USUniversity of Southern California · US
Funding
Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0MCannabinergic Medications for Methamphetamine AddictionR37DA023142 · NIDA · NORTHEASTERN UNIVERSITY · PI MAKRIYANNIS, ALEXANDROS · 2007 to 2016
$7.1MStructure and Function of CB2 ReceptorR01DA045020 · NIDA · NORTHEASTERN UNIVERSITY · PI BOHN, LAURA M., KATRITCH, VSEVOLOD · 2017 to 2021
$3.9MStructure Function of CB1 Cannabinoid ReceptorR01DA041435 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KATRITCH, VSEVOLOD, MAKRIYANNIS, ALEXANDROS · 2016 to 2020
$3.6MThe structural plasticity of chemokine and gp120 recognition by CCR5R01AI118985 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M, KUFAREVA, IRINA · 2015 to 2019
$2.7MChemokine interaction with CXCR4 and ACKR3: structure and activation mechanismsR01GM117424 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M, KUFAREVA, IRINA · 2016 to 2019
$2.2MRational discovery of new DOR chemotypes to prevent addiction and overdoseR21DA038858 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KATRITCH, VSEVOLOD · 2015 to 2016
$410kRational Anthrax Vaccine with Structural Epitopes on VLPR43AI052969 · NIAID · PLEXUS VACCINE · PI KATRITCH, VSEVOLOD · 2002 to 2002
$98kNIAID NIH HHS R01 AI118985NIAID NIH HHS R43 AI052969NIDA NIH HHS P01 DA009158NIDA NIH HHS R01 DA041435NIDA NIH HHS R01 DA045020NIDA NIH HHS R21 DA038858NIDA NIH HHS R37 DA023142NIGMS NIH HHS R01 GM117424
Abstract
Cannabinoid receptor 1 (CB
Indexed as
Binding SitesCannabinoid Receptor AntagonistsCannabinoidsCannabisCrystallography, X-RayDronabinolEndocannabinoidsHumansLigandsMorpholinesProtein BindingProtein Conformation, alpha-HelicalPyrazolesReceptor, Cannabinoid, CB1AM6545Cannabinoid Receptor AntagonistsCannabinoidsDronabinolEndocannabinoidsLigandsMorpholinesPyrazolesReceptor, Cannabinoid, CB1AM6538cannabinoid receptor CB1cell signallingcrystal structureG protein-coupled receptormarijuanarimonabantstabilizing antagonistTHC
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.